Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway.
Alzheimer's disease (AD) represents the most common age-related neurodegenerative disorder. It is characterized by the invariant accumulation of the beta-amyloid peptide (Abeta), which mediates synapse loss and cognitive impairment in AD. Current therapeutic approaches concentrate on reducing Abeta levels and amyloid plaque load via modifying or inhibiting the generation of Abeta. Based on in vivo two-photon imaging, we present evidence that side effects on the level of dendritic spines may counteract the beneficial potential of these approaches. Two potent gamma-secretase inhibitors (GSIs), DAPT (N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester) and LY450139 (hydroxylvaleryl monobenzocaprolactam), were found to reduce the density of dendritic spines in wild-type mice. In mice deficient for the amyloid precursor protein (APP), both GSIs had no effect on dendritic spine density, demonstrating that gamma-secretase inhibition decreases dendritic spine density via APP. Independent of the effects of gamma-secretase inhibition, we observed a twofold higher density of dendritic spines in the cerebral cortex of adult APP-deficient mice. This observation further supports the notion that APP is involved in the modulation of dendritic spine density--shown here for the first time in vivo.
Bittner
Tobias
T
Center of Neuropathology and Prion Research, Ludwig-Maximilians-Universität, Munich, Germany.
Fuhrmann
Martin
M
Burgold
Steffen
S
Jung
Christian K E
CK
Volbracht
Christiane
C
Steiner
Harald
H
Mitteregger
Gerda
G
Kretzschmar
Hans A
HA
Haass
Christian
C
Herms
Jochen
J
D000544:Alzheimer Disease / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016564:Amyloid beta-Protein Precursor / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D000818:Animals; D049229:Dendritic Spines / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology*; D004151:Dipeptides / Q000494:pharmacology; D005260:Female; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics
D016564:Amyloid beta-Protein Precursor; D004151:Dipeptides; C419410:N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; D053829:Amyloid Precursor Protein Secretases
Neural Comput. 2002 Jun;14(6):1283-310
12020447
J Neuropathol Exp Neurol. 1994 Sep;53(5):438-47
8083687
Neuron. 2004 Apr 8;42(1):23-36
15066262
Arch Neurol. 2008 Aug;65(8):1031-8
18695053
J Pharmacol Exp Ther. 2003 Jun;305(3):864-71
12626636
J Neurosci. 2005 Aug 3;25(31):7278-87
16079410
J Neurosci. 2006 Jul 5;26(27):7212-21
16822978
EMBO Rep. 2002 Jul;3(7):688-94
12101103
J Neurochem. 2001 Jan;76(1):173-81
11145990
J Neurosci. 2007 Jun 6;27(23):6224-33
17553995
Nature. 2006 Jun 22;441(7096):979-83
16791195
Neuron. 2005 Jan 20;45(2):279-91
15664179
Neuron. 2006 Dec 7;52(5):831-43
17145504
Ann Neurol. 1991 Oct;30(4):572-80
1789684
Cell. 2007 Oct 19;131(2):215-21
17956719
Science. 2002 Oct 25;298(5594):789-91
12399581
Nat Neurosci. 2006 Sep;9(9):1117-24
16892056
Nature. 2002 Dec 19-26;420(6917):812-6
12490949
EMBO J. 2004 Feb 11;23(3):483-8
14749724
Nat Neurosci. 2004 Nov;7(11):1181-3
15475950
Neuron. 2003 Mar 27;37(6):925-37
12670422
Nature. 2002 Dec 19-26;420(6917):788-94
12490942
Nature. 2005 Jul 14;436(7048):261-5
16015331
J Neurosci. 2005 Sep 28;25(39):8898-902
16192379
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6158-62
8650236
Neuron. 2000 Oct;28(1):41-51
11086982
J Neurosci. 2006 Mar 15;26(11):3021-9
16540580
Nat Rev Mol Cell Biol. 2004 Jun;5(6):499-504
15173829